Amyris Inc (NASDAQ:AMRS) shares saw unusually-strong trading volume on Friday . Approximately 3,228,100 shares were traded during trading, an increase of 409% from the previous session’s volume of 634,754 shares.The stock last traded at $5.59 and had previously closed at $5.50.

A number of research firms recently commented on AMRS. ValuEngine raised Amyris from a “strong sell” rating to a “sell” rating in a research note on Friday, February 23rd. Zacks Investment Research raised Amyris from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. B. Riley set a $10.00 price target on Amyris and gave the company a “buy” rating in a research note on Tuesday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Amyris in a research note on Monday, April 2nd. Finally, BidaskClub downgraded Amyris from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $9.13.

The company has a market cap of $280.99 million, a P/E ratio of -1.83 and a beta of 0.07. The company has a debt-to-equity ratio of -0.35, a current ratio of 0.67 and a quick ratio of 0.62.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($1.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($1.31). The company had revenue of $23.00 million during the quarter, compared to analyst estimates of $24.12 million. During the same period in the previous year, the business posted ($0.13) earnings per share. The firm’s quarterly revenue was up 77.2% compared to the same quarter last year. equities research analysts predict that Amyris Inc will post -1.92 earnings per share for the current fiscal year.

In other Amyris news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of Amyris stock in a transaction dated Monday, May 7th. The stock was sold at an average price of $6.54, for a total value of $622,359.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 21.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in AMRS. Hudson Bay Capital Management LP bought a new position in Amyris in the fourth quarter valued at about $451,000. Compagnie Lombard Odier SCmA grew its holdings in shares of Amyris by 60.0% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 39,000 shares during the last quarter. B. Riley Financial Inc. bought a new stake in shares of Amyris during the first quarter worth about $294,000. Crown Advisors Management Inc. bought a new stake in shares of Amyris during the first quarter worth about $669,000. Finally, KBC Group NV grew its holdings in shares of Amyris by 37.4% during the first quarter. KBC Group NV now owns 62,465 shares of the biotechnology company’s stock worth $418,000 after purchasing an additional 16,995 shares during the last quarter. Hedge funds and other institutional investors own 23.72% of the company’s stock.

About Amyris

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.